IPAR vs SKIN

For growth investors, Inter Parfums, Inc.

(IPAR) is the stronger pick with 2. 5% revenue growth year-over-year, versus -10. 0% for The Beauty Health Company (SKIN). Inter Parfums, Inc. (IPAR) offers the better valuation at 17. 9x trailing P/E (19. 4x forward), making it the more compelling value choice. Analysts rate Inter Parfums, Inc. (IPAR) a "Hold" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Inter Parfums, Inc.

(IPAR) delivered a total return of +41. 9%, compared to -92. 9% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: IPAR returned +255. 2% versus SKIN's -91. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Inter Parfums, Inc.

(IPAR) is the lower-risk stock at 0. 54β versus The Beauty Health Company's 2. 00β — meaning SKIN is approximately 267% more volatile than IPAR relative to the S&P 500. On balance sheet safety, Inter Parfums, Inc. (IPAR) carries a lower debt/equity ratio of 20% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Inter Parfums, Inc.

(IPAR) is pulling ahead at 2. 5% versus -10. 0% for The Beauty Health Company (SKIN). On earnings-per-share growth, the picture is similar: The Beauty Health Company grew EPS 55. 6% year-over-year, compared to 2. 3% for Inter Parfums, Inc.. Over a 3-year CAGR, IPAR leads at 11. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Inter Parfums, Inc.

(IPAR) is the more profitable company, earning 11. 3% net margin versus -3. 2% for The Beauty Health Company — meaning it keeps 11. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IPAR leads at 18. 2% versus -6. 9% for SKIN. At the gross margin level — before operating expenses — SKIN leads at 65. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for SKIN: 42.

9% to $1. 30.

In this comparison, IPAR (3.

4% yield) pays a dividend. SKIN does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Inter Parfums, Inc.

(IPAR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 54), 3. 4% yield, +255. 2% 10Y return). The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IPAR: +255. 2%, SKIN: -91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Consumer Defensive sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IPAR is a small-cap deep-value stock; SKIN is a small-cap quality compounder stock. IPAR pays a dividend while SKIN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.